Valuation of an integrin-targeting oncology asset

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...
Learn More

Clinical and regulatory due diligence of an asset targeting pre-term birth complications

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...
Learn More

Due Diligence on DNA damage response assets

Challenge: An oncology company with a ‘hub and spoke’ structure wished to commission an expert third-party due diligence on one of its spin-out companies in support of its next investment round. The...
Learn More

Due diligence on life cycle management strategies for acute care assets

Challenge: Our client was a pharmaceutical company considering an acquisition of two approved assets and required expert due diligence on the clinical, regulatory and manufacturing aspects of the two...
Learn More

Indication prioritization for oligonucleotide-based therapeutics targeting age-related disorders

Challenge: A university spinout was developing oligonucleotide therapeutics to address age-related disorders. The company wanted to understand the most attractive lead indications in which to focus...
Learn More

Clinical protocol review in oncology

Challenge A biopharma company developing microbiome therapeutics asked Alacrita to conduct a detailed protocol review of a clinical study designed for its lead asset in patients with advanced solid...
Learn More

Asset scouting for small molecule assets in CNS

Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external innovation. The company...
Learn More

Asset Scouting for Psychoactive Drugs

Challenge: A biotechnology company with clinical-stage assets positioned in several neuropsychiatric disorders wanted to supplement its internal pipeline with external innovation. The company wanted...
Learn More

Gene therapy technology opportunity assessment

Challenge: A cell and gene therapy platform company developing a scalable AAV production system, requested Alacrita’s guidance on the priority order for AAV vector capsid serotype release and the...
Learn More

Indication triaging for AAV-based gene therapies

Challenge: A biopharmaceutical company developing novel immunomodulatory technology was exploring the potential clinical use of its lead candidate in combination with AAV based gene therapies to...
Learn More

Regulatory analysis of rejected marketing authorization & response strategy

Challenge: Our client, a major generics and biosimilars player, was developing a generic version of a major therapeutic. It had submitted a dossier for marketing authorization in the EU which was...
Learn More

Regulatory strategy for an ophthalmology product based on repurposing

Challenge: An ophthalmology specialty pharma company, for whom we had previously conducted due diligence, retained Alacrita to advise on the regulatory strategy for a new product based on repurposing...
Learn More
1 2 3 4 5 ... 29
Next

Need biotech consulting support? We can help.

Contact us today to learn how our pharma & biotech consulting expertise can serve your project.

Contact us

Explore our biotech & life science consulting services

© 2023 Alacrita Holdings Limited  |   Pharma & Biotech Consulting

Alacrita Consulting 
2 Royal College St
London, UK
NW1 0NH

Registered in England & Wales.
No. 10530608


One Broadway
Floor 14
Cambridge, MA 02142

Registered in Massachusetts.